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Background: Nucleolin is a protein over-expressed on the surface of activated cells. Recent studies have underlined
the involvement of cell surface nucleolin in angiogenesis processes. This cell surface molecule serves as a receptor
for various ligands implicated in pathophysiological processes such as growth factors, cell adhesion molecules like
integrins, selectins or laminin-1, lipoproteins and viruses. N6L is a synthetic multimeric pseudopeptide that binds
cell surface expressed nucleolin and inhibits cell proliferation.
Results: In the present work, we further investigated the mechanisms of action of pseudopeptide N6L on
angiogenesis using HUVECs. We provide evidence that N6L inhibits the in vitro adhesion, proliferation and
migration of HUVECs without inducing their apoptosis. In addition, we found that N6L downregulates MMP-2 in
HUVECs. The above biological actions are regulated by SRC, ERK1/2, AKT and FAK kinases as we found that N6L
inhibits their activation in HUVECs. Finally, down regulation of nucleolin using siRNA demonstrated the implication
of nucleolin in the biological actions of these peptides.
Conclusions: Taken together, these results indicate that N6L could constitute an interesting therapeutic tool for
treating diseases associated with excessive angiogenesis.
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A multifunctional protein, nucleolin is ubiquitously
expressed in exponentially growing eukaryotic cells. It was
first described in 1973 as a protein involved in ribosome
biogenesis and also in DNA and RNA metabolism [1].
More recently, nucleolin was shown to shuttle between
cytoplasm and cell surface. In the cytoplasm, it provides a
post-transcriptional regulation of strategic mRNA, partici-
pates in rRNA maturation and ribosome assembly and is
involved in nucleo-cytoplasmic transport [1,2]. On the cell
surface, it serves as a low affinity receptor for several
ligands such as certain growth factors [3].
Following the first report of surface expression in hepa-
tocarcinoma cells [4], more data have been added for the
enhanced expression of nucleolin on the surface of tumor
and endothelial cells, and in endothelial cells of the tumor
vasculature [3-5] in which its expression is constantly
induced [6]. These data, point out the involvement of cell-
surface expressed nucleolin in cell proliferation in tumor* Correspondence: katsopan@upatras.gr
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reproduction in any medium, provided the orcell growth but also in activated endothelial cells. The ex-
pression of nucleolin is enhanced on the surface of endo-
thelial cells upon stimulation with the vascular endothelial
growth factor (VEGF), and the functional blockade or
down regulation of surface nucleolin in endothelial cells
inhibits the migration of endothelial cells and prevents
capillary-tubule formation [7].
Several reports have pointed out molecules related to
cell proliferation or cell differentiation as ligands for cell
surface nucleolin. Among these molecules are the hep-
atocyte growth factor, the heparin affin regulatory pep-
tide, midkine, epithelial growth factor receptor ErbB and
endostatin, which all play a significant role in tumor de-
velopment and angiogenesis processes [8-13]. In
addition several molecules like laminin-1, factor J, L-
and P-selectins which regulate cell adhesion, leukocyte
trafficking, inflammation and angiogenesis are also sur-
face nucleolin binding proteins [14-17]. Furthermore,
urokinase which is involved in mechanisms regulating
pericellular proteolysis, cell-surface adhesion and mito-
genesis, binds and is co-internalized with surface nucleo-
lin [18,19].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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binding multivalent pseudopeptide N6L suppressed both
tumor growth and angiogenesis [20]. In vitro, N6L
reduces tumor cell growth in soft agar assay in several
carcinoma cell lines and the proliferation of endothelial
cells. These activities in both tumor and activated endo-
thelial cells lead to tumor growth inhibition in breast
carcinoma MDA-MB 231 xenografts in athymic nude
mice without displaying any toxicity in normal tissues
[20]. Finally, N6L promotes tumor cell death in vitro
and in vivo experiments [20].
In this study, we have investigated the anti-angiogenic
activities and the mechanism of action of N6L on human
umbilical vein endothelial cells (HUVEC) and the role of
nucleolin in these activities.
Results
N6L inhibits adhesion, proliferation and migration of
HUVECs
The effect of N6L on the adhesion of HUVECs was first
investigated. As shown in Figure 1A, N6L significantly
inhibited the adhesion in a concentration-dependent
manner, reaching a maximal effect at a concentration of
50 μΜ yielding 40% inhibition compared to the control
(Figure 1A). All cells will adhere if left for more than 6 h
so we investigated the effect of N6L on the proliferation
of HUVECs. As shown in Figure 1B, N6L inhibited cell
proliferation in a concentration dependent manner,Figure 1 N6L inhibits the in vitro adhesion, proliferation, migration a
An equal number of HUVECs were incubated with increasing concentration
adherent cells were measured by the crystal violet assay. Results are expres
least 3 independent experiments (B). Inhibition of HUVECs proliferation by
concentrations of N6L. Cell proliferation was quantified by crystal violet sta
mean values ± SE from at least 3 independent experiments. (C) Migration
filters (8 μm pores) was filled with growth media containing 0.5% BSA, and
resuspended in a growth medium containing 0.5% BSA, and transferred int
pores, were fixed, stained and quantified by counting the entire area of ea
mean values ± SE from at least 3 independent experiments. (D) Confluent
in the presence of increasing concentrations of N6L. 48 h later the plates whaving a maximal effect at a concentration of 50 μΜ
(Figure 1B). The effect of N6L on HUVEC chemotaxis
indicated that N6L inhibited chemotactic migration in a
concentration-dependent manner with a maximal effect
(61% inhibition relative to control) observed at the con-
centration of 50 μM (Figure 1C). Furthermore, the effect
of N6L has been studied in wound-closure assays. As
shown in Figure 1D, N6L used at a concentration of
10 μM completely inhibits HUVEC motility.
To confirm that N6L has a direct effect on adhesion
and migration and secondarily on proliferation without
affecting cell survival, a cytotoxic assay using HUVEC,
treated or not with various concentrations of N6L, has
been performed. As shown in Figure 2, treatment of
HUVEC with N6L for 24 h did not induce apoptosis.
Early apoptotic cells, which are in the beginning of
apoptosis, are distinguished from already dead cells (late
apoptosis). The data indicated that treatment with N6L
in various concentrations for 24 h has no effect on the
survival of HUVECs and confirmed that N6L has a dir-
ect effect on endothelial cells adhesion and migration
and secondarily on their proliferation.
N6L down-regulates MMP-2 in HUVEC
We next studied the effect of N6L on the activation of
Matrix Metalloproteinases (MMPs) which are involved
in the degradation of extracellular matrix and required
for cell migration. MMPs play a crucial role innd motility of HUVECs. (A) Inhibition of HUVEC cell adhesion by N6L.
s of N6L for 30 min before seeding. After a 45 min incubation period,
sed as % change relative to control and are mean values ± SE from at
N6L. Cells were cultured for 3 days in the presence of increasing
ining. Results are expressed as % change relative to control and are
of cells through Transwell filters. The lower compartment of Transwell
increasing concentrations of N6L. An equal number of HUVECs was
o Transwell inserts. Cells that successfully migrated through the filter
ch filter. Results are expressed as % change relative to control and are
cell monolayers were scratched and cells were left to heal the wound
ere photographed. The dashed lines indicate the remaining wound.
Figure 2 N6L does not induce apoptosis of HUVECs. Endothelial cells were incubated with increasing concentrations of N6L and 24 h later
the number of apoptotic cells was measured by FACS analysis (A and C). Endothelial cells cultured in the presence of H2O2 were used as positive
control (B).
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cell’s migration. MMP-2 is expressed in endothelial cells
as well as in most of the cell types and is important for
endothelial cell migration and vascular remodelling dur-
ing angiogenesis [21,22]. It also facilitates the migration
of tumor cells [23]. The results showed that MMP-2
activity was markedly reduced by 1 μM of N6L
(Figure 3A). We further demonstrated that N6L sup-
pressed the expression of MMP-2 mRNA determined by
RT-PCR (Figure 3B). The results indicated that both en-
zyme activity and expression of MMP-2 was inhibited
by N6L.
The results suggested that N6L and therefore nucleo-
lin might affect the expression of genes involved in pro-
teolytic activation.
Inhibition of SRC, FAK, AKT and ERK1/2 activation during
N6L stimulation of HUVECs in vitro
Several studies have indicated that the SRC, FAK, AKT
and MAPK members are involved in the signaling cas-
cade that regulates angiogenesis [24,25]. Consequently,
the effects of N6L on the phosphorylation status of these
molecules in HUVECs were investigated.
As shown in Figure 4A, N6L promoted a decrease in
SRC phosphorylation within 15 min in a concentration
dependent manner with a maximal effect (80% inhibition
relative to control) at a concentration of 10 μΜ. Simi-
larly, we found that FAK, AKT and ERK1/2 were also
inactivated after a15-min incubation with N6L in a con-
centration dependent manner with a maximal inhibition
of more than 75% as compared to the control.Taken together, these data indicated that N6L inhibits
the phosphorylation of all of these kinases in a dose-
dependent manner (Figure 4A, B, C and D). Results
showed that the anti-angiogenic action of N6L might
partly occur through a suppression of SRC, FAK, AKT and
ERK pathways, but further research is needed in order to
understand the mechanism of action of N6L and how it
inhibits the activation of these signaling pathways.
Down regulation of Nucleolin expression inhibits
adhesion and proliferation of HUVECs and blocks the
inhibitory action of N6L
Previous reports have shown that N6L interacts specific-
ally with cell surface nucleolin [20,26]. N6L has been
reported to also bind nucleophosmin on the cell surface
but with considerably lower affinity than nucleolin [20,26].
In order to confirm that N6L exerts the previously
described biological actions mainly through nucleolin, as
well as the involvement of cell-surface nucleolin in these
effects, we transiently transfected HUVECs with a siRNA
targeting the mRNA of nucleolin. In parallel, HUVECs
were transiently transfected with a siRNA that does not
target any mRNA (negative control) (data not shown).
The analysis of the expression of NCL indicates that
using specific siRNA targeting nucleolin mRNA results
in a reduction in the levels of mRNA and protein up to
80% respectively (Figure 5A and B).
As shown in (Figure 5C and D), NCL knockdown
blocked the inhibitory effect of N6L in HUVECs prolif-
eration and adhesion respectively. Moreover, the same
experiment shows that nucleolin is a crucial factor in
Figure 3 N6L down-regulates MMP-2 in HUVECs. (A) Endothelial
cells were cultured in a minimal medium with increasing
concentrations of N6L and 8 h later the supernatants were analyzed
for MMP-2 activity by zymography. Results are expressed as %
change relative to control and are mean values ± SE from at least 3
independent experiments. (B) Endothelial cells were incubated with
increasing concentrations of N6L and 24 h later total RNA was
extracted from the cells, RT-PCR reactions were performed using
specific primers for MMP-2 or GAPDH mRNAs, the PCR products
were analyzed in agarose gels and quantified. Results are expressed
as % change relative to control and are mean values ± SE from at
least 3 independent experiments.
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down-regulation of nucleolin expression by itself results
in the inhibition of proliferation and adhesion.
Down regulation of Nucleolin expression inhibits SRC and
ERK1/2 activation in HUVECs and blocks the inhibitory
action of N6L
In this study, we show that N6L inhibits phosphorylation
of several kinases implicated in angiogenesis pathways in
many ways.
To confirm that N6L signaling takes place mainly
through nucleolin interaction, we tested the N6L effect
on activation of SRC and ERK1/2 of transiently trans-
fected HUVECs with siRNA for nucleolin mRNA. As
shown in (Figure 6A and B), the phosphorylation levels
of SRC and ERK1/2 are induced on transiently trans-
fected HUVECs compared with wild type cells, while
nucleolin knockdown blocked N6L-induced SRC and
ERK1/2 inactivation.
Taken together, these results indicate that N6L/nucleo-
lin interaction affects various signal transduction path-
ways that reduce the phosphorylation levels of these
signal transduction molecules, and are involved in the
inhibition of cellular adhesion and proliferation.
Discussion
Cell-surface nucleolin has been described by several stud-
ies as a molecule that is involved in the growth of tumor
cells as well as in angiogenesis [3,20,26,27]. Effective inhib-
ition of tumor cell proliferation and impairment of angio-
genesis have been succeeded by targeting surface
nucleoproteins, like nucleolin, with N6L and HB-19
[20,26,27]. Therefore, functional blockade of surface
nucleoproteins seems to result in a general inhibitory
mechanism that is not specific to a single pathway related
to one growth factor implicated in carcinogenesis.
In previous studies, our group has shown the dual ac-
tion of N6L and HB-19 on tumor and endothelial cells
pointing out surface nucleoproteins as an important
anticancer therapy target [20,27].
N6L, which like HB-19, binds nucleolin at the RGG
domain of its C-terminal end, was synthesized aiming
the improvement of HB-19 biological actions. N6L pre-
sents hexavalently the pseudo-tripeptide Lysψ(CH2N)-
Pro-Arg while HB-19 presents it pentavalently. The
inhibitory action of N6L regarding HIV-1 entry is 4-fold
compared to that of HB-19 and the down-regulation of
surface/cytoplasmic nucleolin is greater in cells treated
with N6L compared to cells treated with HB-19 [26].
Furthermore, N6L showed greater inhibitory action in
tumor cells growth compared to HB-19 [20]. N6L, but
not HB-19, has been reported to also bind nucleophos-
min on the cell surface but with considerably lower
affinity than nucleolin [20,26].
Figure 4 N6L signaling down-regulates pSRC, pFAK, pAKT and pERK1/2. Western blot analysis of phosphorylated SRC, FAK, AKT and ERK1/2,
in cells stimulated by increasing concentrations of N6L for 15 minutes. The blots were stripped and re probed for total SRC or HSC70. Results are
expressed as % change relative to the control and are mean values ± SE from at least 3 independent experiments.
Figure 5 Effect of nucleolin (NCL) knockdown on N6L biological actions. Down-regulation of nucleolin (NCL) mRNA (A) and protein (B)
using specific siRNA targeting nucleolin mRNA. Effect of N6L (10μΜ) on proliferation (C) and adhesion (D) of HUVECs. The last two bars of each
diagram indicate HUVECs that were transiently transfected with siRNA targeting nucleolin (NCL). Results are expressed as % change relative to
control and are mean values ± SE from at least 3 independent experiments.
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Figure 6 Effect of nucleolin (NCL) knockdown on N6L-induced signal transduction. Western blot analysis of phosphorylated SRC and ERK1/
2 in HUVECs stimulated with 10 μM N6L for 15 minutes. The blots were stripped and re probed for HSC70. The last two bars of each diagram
indicate HUVECs that were transiently transfected with siRNA targeting nucleolin. Results are expressed as % change relative to control and are
mean values ± SE from at least 3 independent experiments.
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actions of N6L in HUVECs. We found that N6L inhibits
in vitro HUVEC cell adhesion, migration and motility in
a concentration dependent manner (Figure 1A, C and
D). If left for more than 6 h, HUVECs will adhere and
migrate even in the presence of N6L(data not shown),
therefore we investigated the effect of N6L in prolifera-
tion of HUVECs showing that it is also inhibited, even if
it is a secondary effect (Figure 1B). The inhibitory effect
of N6L on angiogenesis [20], as well as on HUVECs mi-
gration and motility may be associated with down regu-
lation of MMP-2. HB-19, which is similar to N6L, was
shown to down regulate MMP-2 expression [28,29]. We
found that both enzyme activity and expression of
MMP-2 were inhibited by N6L (Figure 3). Furthermore,
we found that N6L treatment shows no toxicity in
HUVECs in vitro, as N6L didn’t induce apoptosis
(Figure 2). N6L induces apoptosis of tumor cells in vitro
and reduces tumor growth in mice without evidence of
toxicity [20]. N6L and other Nucants are reported to
exert distinct inhibitory mechanisms depending on the
malignant tumor cell type indicating that the capacity of
Nucant to induce cell death is by a selective mechanism
[20,26]. The lack of translocation of N6L to the nucleus
probably accounts for its lack of toxicity [20,26]. The
mechanism through which N6L induces apoptosis in
some tumor cells without affecting cell viability in other
tumor cells and normal cells, like HUVECs, remains to
be investigated.
Ligant binding to surface nucleolin could generate
intracellular Ca2+ membrane fluxes and initiate signal
transduction events [30]. HB-19 binds the C-terminal
RGG domain of cell-surface expressed nucleolin andblocks its function as a receptor or binding molecule for
various ligands [31,32]. N6L also binds the C-terminal
RGG domain of cell-surface expressed nucleolin and
therefore it might exert its biological action in a similar
way. In order to identify the signaling pathways that
N6L affects and through which exerts its biological ac-
tion, we investigated the effect of this peptide on well
known angiogenic signaling pathways mediated by many
of these ligands of nucleolin. We found that N6L inhibits
the phosphorylation levels of SRC, FAK, AKT, and ERK1/2
in a concentration-dependent manner showing that the
anti-angiogenic action of N6L might partly occur through
suppressing SRC, FAK, AKTand ERK pathways.
Down regulating nucleolin, we found that the prolifera-
tion and adhesion of HUVECs was inhibited, highlighting
the importance of nucleolin in these biological actions
(Figure 5C and D). To confirm that our siRNA was spe-
cific for NCL we examined the effect of siRNA on the ex-
pression of GAPDH mRNA as shown in Figure 5A and
other molecules such as tubulin (data not shown).
The inhibitory effect of N6L on cellular proliferation
and adhesion was almost completely blocked in the
transfected HUVECs compared to the wild type
(Figure 5C and D last two columns). Furthermore, the
phosphorylation levels of SRC and ERK1/2 are induced
on transiently transfected HUVECs compared with wild
type cells (Figure 6, first and third columns), while
nucleolin knockdown blocked N6L-induced SRC and
ERK1/2 inactivation (Figure 6 last two columns). In
Figure 5B the reduction of HSC70 levels in siRNA trans-
fected cells does not indicate secondary inhibitory effects
of our siRNA on the expression of cellular proteins. We
used HSC70 for western blot normalization and its
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of cells due to the inhibitory effect of NCL knock-down
on cell proliferation. Taken together, these results indi-
cate that the complex N6L/nucleolin interaction triggers
a signal transduction pathway that reduces the phos-
phorylation levels of these signal transduction molecules,
and also that it inhibits cellular adhesion and prolifera-
tion. Down regulation of mRNA of NCL using siRNA is
reported to reduce surface nucleolin [7]. Additionally,
the expression of nucleolin on the surface of endothelial
cells is due to the constant induction of nucleolin
mRNA, as NCL mRNA and cell-surface-NCL have half-
life time of about 45-90 min, whereas nuclear NCL has
more than 24 h [6]. Therefore, although we did not dis-
tinguish surface and nuclear nucleolin, we can presume
with relative safety, that cell surface NCL levels were
reduced in our experimental conditions. As a result, we
can hypothesize the involvement of surface NCL in N6L
action and consider NCL the main molecule through
which N6L exerts its action, knowing that there is more
research to be done in order to extrapolate that the
mechanism by which N6L exerts its action is through
surface NCL.
Conclusions
In summary, in this study we shed light on the role of
cell surface nucleoproteins in the regulation of their
binding proteins signaling and activity in HUVECs.
These results indicate that N6L could constitute an
interesting tool to inhibit angiogenesis. This possibility is
reinforced by the fact that these multimeric pseudopep-
tides are synthetic molecules which are stable in serum,
lack tissular toxicity and whose production can easily be




Human umbilical vein endothelial cells (HUVEC) were
isolated from umbilical cord vein by collagenase diges-
tion as previously described [33] and used at passages
2–4. The cells were grown as monolayers in medium
M199 supplemented with 15% fetal bovine serum (FBS),
150 μg/ml of endothelial cell growth supplement, 5 U/ml
heparin sodium, 100 U/ml penicillin-streptomycin and
50 μg/ml gentamycin. Cultures were maintained at 37°C,
5% CO2 and 100% humidity.
Materials
Cell culture reagents were from BiochromKG (Seromed,
Germany). All other reagents were purchased from
Sigma-Aldrich. Monoclonal antibodies against pSRC-
kinase (Tyr416), pFAK (Tyr925), pAKT (Ser473),
pERK1/2 (Thr202/Tyr204) and total SRC were purchasedfrom Cell Signaling Technology. Polyclonal antibodies
against HSC70 and NCL (nucleolin) were purchased
from Santa Cruz Biotechnology, Inc.
Peptide construct
N6L was synthesized, as previously described, using the
solid phase peptide methodology [20].
Cell proliferation assay
An equal number of cultured HUVECs in medium con-
taining 15% FBS were left to adhere for 20 h in a cell
culture microplate. Then, they were treated with differ-
ent N6L concentrations and were allowed to proliferate
for 3 days. The cell number was estimated by the crystal
violet assay. Data are the mean ± SEM of at least three
independent experiments.
Adhesion assay
24-well culture plates were coated with 1% v/v gelatin
for 20 min at 37°C. 50,000 resuspended cells incubated
in M199 medium with different concentrations of N6L
for 30 min and then seeded. After a 30 min incubation
period unattached cells were removed by shaking the
plates at 2,000 rpm for 10 sec, and by three washes with
PBS. Attached cells were fixed with methanol and
stained with crystal violet.
Boyden chamber assay
Migration assays were performed in a 24-well microche-
motaxis chamber (Costar, Avon, France), using untreated
polycarbonate membranes with 8 μm pores. HUVECs
were harvested and resuspended at a concentration of
105 cells/0.1 ml in the corresponding medium contain-
ing 0.25% bovine serum albumin (BSA). The bottom
chamber was filled with 0.6 ml of the corresponding
medium containing 0.25% BSA and N6L. The upper
chamber was loaded with 105 cells and incubated for 4 h
at 37°C. After completion of the incubation, filters were
fixed. Non-migrated cells were scrapped off the upper
side of the filter, and filters were stained with crystal vio-
let. The number of migrated cells was quantified by
counting the entire area of the filter using a grid and an
Optech microscope at a 20× magnification.
In vitro endothelial cell wound healing assay
HUVECs were cultured in 6-well plates at 2×105 cells/
well as confluent monolayers. The monolayers were
wounded in a line across the well with a 200 μl standard
pipette tip. The wounded monolayers were then washed
twice with PBS to remove cell debris and were incubated
with increasing concentrations of N6L for 48 h. The area
of the initial wound was photographed using a charge-
coupled device camera connected to an inverted micro-
scope (Axiovert 35; Zeiss, Thornwood, NY). The wound
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of the initial wound.
Western blot analysis
Cells were starved for 4 h and then incubated with differ-
ent concentrations of N6L for 15 min. Cells were subse-
quently washed twice with PBS and lysed in 250 μl 2X
SDS loading buffer under reducing conditions. Proteins
were separated by SDS-PAGE and transferred to an
Immobilon-P membrane for 3 h in 48 mM Tris pH 8.3,
39 mM glycine, 0.037% SDS, and 20% methanol. The
membrane was blocked in TBS containing 5% non-fat
milk and 0.1% Tween 20 for 1 h at 37°C. Membranes were
then probed with primary antibody overnight at 4°C under
continuous agitation. All antibodies were used at a 1:1000
dilution. The blot was then incubated with the appropriate
secondary antibody coupled to horseradish peroxidase,
and bands were detected with the ChemiLucent Detection
System Kit (Chemicon International Inc., CA) according
to the manufacturer’s instructions. Where indicated, blots
were stripped in buffer containing 0.5 mM Tris HCl pH
6.8, 2% SDS, 100 mM 2-mercaptoethanol for 30 min at
56°C and re probed. A quantitative estimation of band size
and intensity was performed through analysis of digital
images using the ImagePC image analysis software (Scion
Corporation, Frederick, MD).
Gelatin zymography
Secreted metalloproteinases were detected and character-
ized by zymography. Conditioned media were obtained by
an 8 h incubation of cells in serum-free media. Condi-
tioned media were loaded onto 10% SDS-PAGE gels that
had been co polymerized with 1 mg/ml gelatin. Electro-
phoresis was carried out under non-reducing conditions
at 100 V for 2 h at 4°C. Gels were washed once for 60 min
in 2.5% Triton X-100 to remove SDS and incubated in
zymogen activator buffer (50 mM Tris–HCl pH 7.6,
10 mM CaCl2, 0.2 M NaCl) for 24 h at 37°C. Gels were
stained with 0.5% Coomassie blue in 30% methanol/10%
acetic acid for 30 min at room temperature and de-stained
in 30% methanol/10% acetic acid three times for 15 min.
The presence of metalloproteinases was indicated by an
unstained (due to proteolysis) zone in the substrate. Both
active forms and pro-enzymes are revealed by this tech-
nique, since exposure of pro-MMPs to SDS during SDS-
PAGE leads to activation without proteolytic cleavage. The
relative amounts of MMPs were quantified by NIH Image
Analysis software. The normalization was based on the
number of cells of each well (using crystal violet method).
Annexin V binding staining
The analysis of annexinV binding was carried out with
an Annexin V-FITC Detection Kit I (PharMingen, San
Diego, CA) according to the manufacturer’s instructions.An equal number of cultured HUVECs in medium con-
taining 15% FBS were left to adhere for 20 h in a cell
culture microplate. They were then treated with different
N6L concentrations and collected after 24 h, washed
twice with cold PBS, centrifuged at 200 g for 5 min and
resuspended in binding buffer at a concentration of 106
cells per ml. 100 μl of the solution were transferred to a
5 ml culture tube and 5 μl of annexin V-FITC and 5 μl
of PI were added. Cells were gently vortexed and incu-
bated for 15 min at room temperature in the dark. Fi-
nally, 400 μl of binding buffer was added to each tube,
and samples were analyzed by FACScan flow cytometer
(Becton Dickinson). For each sample, 10,000 un gated
events were acquired. PI (-)/annexin (+) cells represent
early apoptotic populations and PI (+)/annexin (+) cells
represent late apoptotic populations.
Crystal violet assay
Adherent cells were fixed with methanol and stained
with 0.5% crystal violet in 20% methanol for 20 min.
After gentle rinsing with water, the retained dye was
extracted with 30% acetic acid, and the absorbance was
measured at 595 nm.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
for Nucleolin, MMP2, and GAPDH
Total RNA was extracted using the Nucleospin RNA II
kit (Macherey-Nagel, Germany) according to the manu-
facturer’s instructions. The integrity of isolated RNA was
examined by electrophoresis on a 1% agarose gel con-
taining 0.5 mg/ml ethidium bromide. Specific primers
were as follows:
Nucleolin,
500- TGCCAAGAAGACAGTTACACCA -300 and
500- AGGAACAACTTTTGCAGCTTTC - 300;
MMP2,





The RT-PCR reactions were performed in a single step
with 250 ng of total RNA, using the Qiagen RT-PCR sys-
tem. The RT-PCR products were subjected to electro-
phoresis on 1% agarose gel containing 0.5 mg/ml
ethidium bromide, digitally photographed, and quanti-
fied using image analysis software (Scion Image PC,
Scion Corporation, Frederick, MD).
siRNA transfection
RNA oligonucleotide primers were obtained from Ambion
Inc and the Lipofectamine RNAiMAX Transfection Agent
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were used:
siRNA Nucleolin sense: 500-GGAUAGUUACUGAC
CGGGA-300;
siRNA Nucleolin antisense: 500-UCCCGGUCAGUAA
CUAUCC-300,
HUVECs were plated in 6 wells-plates and incubated
for 24 hours at 37°C. Cells were then transfected at a
final concentration of 10nM siRNA using Lipofectamine
RNAiMAX reagent (Invitrogen) according to the manu-
facturer’s instructions.
Transfection efficiency was evaluated using Silencer
FAM Labelled GAPDH siRNA (Ambion). Negative con-
trol siRNAs from Ambion was also used.
Statistical analysis
Comparisons of the mean values among groups were
performed by means of ANOVA and unpaired Student
t-test. Homogeneity of variances was tested by Levene’s
test. Each experiment included at least triplicate mea-
surements for each condition tested. All results are
expressed as mean ± SE from at least three independent
experiments. Values of p less than 0.05 were accepted as
significant (*p < 0.05, **p < 0.01, ***p < 0.001).
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